Abstract
A group of 29 hypertensive patients were studied for side effects of acebutolol. An antinuclear antibody titre of ≥1/64 developed in 23 per cent of patients during a 12-month course of treatment. Full ophthalmic examination before and after the treatment period showed a statistically significant increase in tear secretion at one year. One patient had a slight worsening of her psoriasis. No patients developed any symptoms or signs of oculomucocutaneous syndrome (OMCS) or systemic lupus erythematosus (SLE).
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Booth R. J., Bullock J. Y., Wilson J. D. Antinuclear antibodies in patients on acebutolol. Br J Clin Pharmacol. 1980 May;9(5):515–517. doi: 10.1111/j.1365-2125.1980.tb05848.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cody R. J., Jr, Calabrese L. H., Clough J. D., Tarazi R. C., Bravo E. L. Development of antinuclear antibodies during acebutolol therapy. Clin Pharmacol Ther. 1979 Jun;25(6):800–805. doi: 10.1002/cpt1979256800. [DOI] [PubMed] [Google Scholar]
- El-Ghobarey A. E., Sloane D. J., Whaley K. The clinical significance of the antinuclear antibody test as a screening procedure for DNA antibodies in SLE. Scott Med J. 1980 Oct;25(4):293–298. doi: 10.1177/003693308002500409. [DOI] [PubMed] [Google Scholar]
- Holt P. J., Waddington E. Oculocutaneous reaction to oxprenolol. Br Med J. 1975 Jun 7;2(5970):539–540. doi: 10.1136/bmj.2.5970.539. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hughes G. R. Hypotensive agents, beta-blockers, and drug-induced lupus. Br Med J (Clin Res Ed) 1982 May 8;284(6326):1358–1359. doi: 10.1136/bmj.284.6326.1358. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Levy M., David D. Immune reactions associated with practolol therapy. Int J Clin Pharmacol Biopharm. 1978 Oct;16(10):479–481. [PubMed] [Google Scholar]
- Petrie J. C. Oculo-mucocutaneous reactions to beta-adrenoceptor antagonists. Br Med J. 1976 Nov 6;2(6044):1134–1134. doi: 10.1136/bmj.2.6044.1134-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Raftery E. B., Denman A. M. Systemic lupus erythematosus syndrome induced by practolol. Br Med J. 1973 May 26;2(5864):452–455. doi: 10.1136/bmj.2.5864.452. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Record N. B., Jr Acebutolol-induced pleuropulmonary lupus syndrome. Ann Intern Med. 1981 Sep;95(3):326–327. doi: 10.7326/0003-4819-95-3-326. [DOI] [PubMed] [Google Scholar]
- Shapiro A., Kimchi A., Rod J. L., Gotsman M. S., Lewis B. S. Ocular effects of acebutolol and propranolol. Metab Pediatr Ophthalmol. 1980;4(2):87–88. [PubMed] [Google Scholar]
- Williamson J., Cant J. S., Mason D. K., Greig W. R., Boyle J. A. Sjögren's syndrome and thyroid disease. Br J Ophthalmol. 1967 Nov;51(11):721–726. doi: 10.1136/bjo.51.11.721. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wilson J. D. Antinuclear antibodies and cardiovascular drugs. Drugs. 1980 Apr;19(4):292–305. doi: 10.2165/00003495-198019040-00004. [DOI] [PubMed] [Google Scholar]
- Wright P. Untoward effects associated with practolol administration: oculomucocutaneous syndrome. Br Med J. 1975 Mar 15;1(5958):595–598. doi: 10.1136/bmj.1.5958.595. [DOI] [PMC free article] [PubMed] [Google Scholar]